Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Incidence and characteristics of melanoma brain metastases developing during treatment with vemurafenib
L. Peuvrel, M. Saint‐Jean, G. Quéreux, et al.
Journal of Neuro-Oncology (2014) Vol. 120, Iss. 1, pp. 147-154
Closed Access | Times Cited: 46

Showing 1-25 of 46 citing articles:

Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma
Sunilkumar Kakadia, Naveen Yarlagadda, Ramez Awad, et al.
OncoTargets and Therapy (2018) Vol. Volume 11, pp. 7095-7107
Open Access | Times Cited: 231
Systemic therapy of brain metastases: non–small cell lung cancer, breast cancer, and melanoma
Marc C. Chamberlain, Christina S. Baik, Vijayakrishna K. Gadi, et al.
Neuro-Oncology (2016) Vol. 19, Iss. 1, pp. i1-i24
Open Access | Times Cited: 201
Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF/MEK inhibitors
Max Schreuer, Geert Meersseman, Sari Van Den Herrewegen, et al.
Journal of Translational Medicine (2016) Vol. 14, Iss. 1
Open Access | Times Cited: 132
Improving drug delivery to primary and metastatic brain tumors: Strategies to overcome the blood–brain barrier
KE Parrish, JN Sarkaria, W. F. Elmquist
Clinical Pharmacology & Therapeutics (2015) Vol. 97, Iss. 4, pp. 336-346
Closed Access | Times Cited: 122
Efflux Transporters at the Blood-Brain Barrier Limit Delivery and Efficacy of Cyclin-Dependent Kinase 4/6 Inhibitor Palbociclib (PD-0332991) in an Orthotopic Brain Tumor Model
Karen E. Parrish, Jenny L. Pokorny, Rajendar K. Mittapalli, et al.
Journal of Pharmacology and Experimental Therapeutics (2015) Vol. 355, Iss. 2, pp. 264-271
Open Access | Times Cited: 92
Improved survival of patients with melanoma brain metastases in the era of targeted BRAF and immune checkpoint therapies
Sarah Sloot, Y. Ann Chen, Xiuhua Zhao, et al.
Cancer (2017) Vol. 124, Iss. 2, pp. 297-305
Open Access | Times Cited: 92
Blocking immunosuppressive neutrophils deters pY696-EZH2–driven brain metastases
Lin Zhang, Jun Yao, Yongkun Wei, et al.
Science Translational Medicine (2020) Vol. 12, Iss. 545
Open Access | Times Cited: 85
Targeted treatment and immunotherapy in leptomeningeal metastases from melanoma
Marnix H. Geukes Foppen, Dieta Brandsma, Christian U. Blank, et al.
Annals of Oncology (2016) Vol. 27, Iss. 6, pp. 1138-1142
Open Access | Times Cited: 81
Clinical Management of Multiple Melanoma Brain Metastases
Sharad Goyal, Ann W. Silk, Sibo Tian, et al.
JAMA Oncology (2015) Vol. 1, Iss. 5, pp. 668-668
Open Access | Times Cited: 79
PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain MetastasesIn VitroandIn Vivo
Heike Niessner, Jennifer Schmitz, Ghazaleh Tabatabai, et al.
Clinical Cancer Research (2016) Vol. 22, Iss. 23, pp. 5818-5828
Open Access | Times Cited: 76
Cerebrospinal fluid concentrations of vemurafenib in patients treated for brain metastatic BRAF-V600 mutated melanoma
L. Sakji-Dupré, Émilie Le Rhun, C. Templier, et al.
Melanoma Research (2015) Vol. 25, Iss. 4, pp. 302-305
Closed Access | Times Cited: 57
Targeted therapy of brain metastases: latest evidence and clinical implications
Rodica Di Lorenzo, Manmeet S. Ahluwalia
Therapeutic Advances in Medical Oncology (2017) Vol. 9, Iss. 12, pp. 781-796
Open Access | Times Cited: 51
Impact of radiation, systemic therapy and treatment sequencing on survival of patients with melanoma brain metastases
Ricarda Rauschenberg, Johannes Bruns, Julia Brütting, et al.
European Journal of Cancer (2019) Vol. 110, pp. 11-20
Open Access | Times Cited: 51
Treatment of brain metastases in the modern genomic era
Ibiayi Dagogo‐Jack, Corey M. Gill, Daniel P. Cahill, et al.
Pharmacology & Therapeutics (2016) Vol. 170, pp. 64-72
Closed Access | Times Cited: 47
Molecular insights into melanoma brain metastases
Dana Westphal, Isabella C. Glitza Oliva, Heike Niessner
Cancer (2017) Vol. 123, Iss. S11, pp. 2163-2175
Open Access | Times Cited: 42
Overview of metastatic disease of the central nervous system
Craig Nolan, Lisa M. DeAngelis
Handbook of clinical neurology (2018), pp. 3-23
Closed Access | Times Cited: 37
Brain metastases from hepatocellular carcinoma: recent advances and future avenues
Shanshan Wang, Anqiang Wang, Jianzhen Lin, et al.
Oncotarget (2017) Vol. 8, Iss. 15, pp. 25814-25829
Open Access | Times Cited: 33
Targeted Therapies for Melanoma Brain Metastases
Anna S. Berghoff, Matthias Preusser
Current Treatment Options in Neurology (2017) Vol. 19, Iss. 4
Open Access | Times Cited: 29
Vemurafenib in leptomeningeal carcinomatosis from melanoma: a case report of near-complete response and prolonged survival
Charalampos S. Floudas, Abhinav Chandra, Yiqing Xu
Melanoma Research (2016) Vol. 26, Iss. 3, pp. 312-315
Closed Access | Times Cited: 25
Targeted Therapies for the Treatment of Brain Metastases in Solid Tumors
Jan‐Paul Bohn, Georg Pall, Guenther Stockhammer, et al.
Targeted Oncology (2016) Vol. 11, Iss. 3, pp. 263-275
Closed Access | Times Cited: 20
Integrative Genomic Analyses of Patient-Matched Intracranial and Extracranial Metastases Reveal a Novel Brain-Specific Landscape of Genetic Variants in Driver Genes of Malignant Melanoma
Renáta Váraljai, Susanne Horn, Antje Sucker, et al.
Cancers (2021) Vol. 13, Iss. 4, pp. 731-731
Open Access | Times Cited: 17
Applications for quantitative measurement of BRAF V600 mutant cell-free tumor DNA in the plasma of patients with metastatic melanoma
Max Schreuer, Geert Meersseman, Sari Van Den Herrewegen, et al.
Melanoma Research (2015) Vol. 26, Iss. 2, pp. 157-163
Closed Access | Times Cited: 18
Tumor DNA Mutations From Intraparenchymal Brain Metastases Are Detectable in CSF
Stephanie Cheok, Azeet Narayan, Anna Arnal Estape, et al.
JCO Precision Oncology (2021), Iss. 5, pp. 163-172
Open Access | Times Cited: 15
Challenges in the Delivery of Therapies to Melanoma Brain Metastases
Gautham Gampa, Shruthi Vaidhyanathan, Brynna Wilken-Resman, et al.
Current Pharmacology Reports (2016) Vol. 2, Iss. 6, pp. 309-325
Open Access | Times Cited: 17
Management of intracranial melanomas in the era of precision medicine
Grace Young, Wenya Linda Bi, Winona Wu, et al.
Oncotarget (2017) Vol. 8, Iss. 51, pp. 89326-89347
Open Access | Times Cited: 17
Page 1 - Next Page

Scroll to top